Investigators presented new rezpegaldesleukin data supporting long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis at the EADV Congress 2026.

The presentation adds to the growing evidence base for rezpegaldesleukin, an investigational interleukin-2 pathway–targeting biologic that dermatologists have tracked across both autoimmune hair-loss and atopic inflammatory indications.

What did the new data cover?

The dataset presented at EADV Congress 2026 addresses two questions that have trailed first-generation biologics in these indications: how long responses hold after initial improvement, and whether disease severity continues to decline with continued treatment.

The reported findings support:

• Long-term durability of response in patients with alopecia areata
• Sustained disease improvement in patients with atopic dermatitis
• Continued safety and efficacy characterization of rezpegaldesleukin across both cohorts

Why durability matters in these indications

For alopecia areata, relapse after treatment withdrawal has complicated clinical management with existing therapies, making long-term maintenance of regrowth a decisive endpoint. For atopic dermatitis, sustained clearance — measured in trials through instruments such as EASI and the peak pruritus NRS — separates durable immunomodulation from temporary symptom suppression.

Rezpegaldesleukin is designed as a preferential interleukin-2 receptor agonist intended to expand regulatory T cells, a mechanism distinct from the cytokine-blocking antibodies that dominate current atopic dermatitis and alopecia areata treatment paradigms.

What comes next

Additional details on effect sizes, cohort sizes and timepoints from the EADV 2026 presentations are expected to inform how rezpegaldesleukin's durability profile positions it against approved and late-pipeline competitors as its development program advances.